When will a SARS-CoV-2 vaccine be available?
A novel vaccine platform requires careful evaluation and should ideally
include toxicological studies in valid animal models. Early progress
towards SARS vaccines has facilitated a “running start” but standards
of care and safety must be maintained. Acceleration rather than omission
of clinical trials is key. Preliminary data from Oxford University is
anticipated by mid-2020.203 Of note, a
dose-escalation, single-center, open-label, non-randomized, phase 1 was
conducted in 108 healthy individuals that received an Ad5 vectored
COVID-19 vaccine. The vaccine was tolerable and immunogenic at 28 days
post-vaccination. SARS-CoV-2-specific antibodies peaked at day 28
post-vaccination and specific T-cell responses were detected from day 14
post-vaccination.209